A proof-of-concept study to assess the effect of ACT-451840 against early Plasmodium falciparum blood stage infection in healthy subjects.

A proof-of-concept study to assess the effect of ACT-451840 against early Plasmodium falciparum blood stage infection in healthy subjects

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12614000781640

Enrollment

Registered

2014-07-21

Start date

2014-06-06

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

A proof-of-concept study to assess the effect of ACT-451840 against early Plasmodium falciparum blood stage infection in healthy subjects

Interventions

Drug Description: Dosage: 500 mg of ACT-451840 Mode of Administration: Oral Suspension Frequency and Duration: Single dose Strategies to monitor adherence: Oral suspension shall be administered in the presence of the investigational site team. Parasite introduction Type of parasite/ dose: malaria inoculum of ~1,800 viable Plasmodium falciparum-infected human erythrocytes Administration: Intravenously Administration time: approximately 7 days prior to ACT-451840 administration.

Study design

Allocation

Non-randomised trial

Intervention model

Single group

Primary purpose

Treatment

Masking

Open (masking not used)

Eligibility

Sex/Gender

Male

Age

18 Years to 50 Years

Healthy volunteers

Yes

Inclusion criteria

Healthy volunteers

Exclusion criteria

Any history of malaria.

Outcome results